Compare · ICCC vs NEOG
ICCC vs NEOG
Side-by-side comparison of ImmuCell Corporation (ICCC) and Neogen Corporation (NEOG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICCC and NEOG operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NEOG is the larger of the two at $2.54B, about 28.4x ICCC ($89.4M).
- NEOG has been more active in the news (11 items in the past 4 weeks vs 4 for ICCC).
- NEOG has more recent analyst coverage (5 ratings vs 0 for ICCC).
- Company
- ImmuCell Corporation
- Neogen Corporation
- Price
- -
- -
- Market cap
- $89.4M
- $2.54B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1987
- 1989
- News (4w)
- 4
- 11
- Recent ratings
- 0
- 5
ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Neogen Corporation
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.
Latest ICCC
- SEC Form 10-Q filed by ImmuCell Corporation
- ImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026
- ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026
- ImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results
- President and CEO Te Boekhorst Paul Francis Olivier bought $75,960 worth of shares (8,000 units at $9.49), increasing direct ownership by 82% to 17,785 units (SEC Form 4)
- ImmuCell Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- ImmuCell Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- ImmuCell Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest NEOG
- SEC Form DEFA14A filed by Neogen Corporation
- SEC Form DEF 14A filed by Neogen Corporation
- Chief Accounting Officer Moylan John Patrick covered exercise/tax liability with 2,365 units of Restricted Stock Units, decreasing direct ownership by 7% to 29,331 units (SEC Form 4)
- CEO Nassif Mikheal covered exercise/tax liability with 20,397 units of Restricted Stock Units, decreasing direct ownership by 44% to 25,655 units (SEC Form 4)
- Chief Accounting Officer Moylan John Patrick was granted 8,584 units of Restricted Stock Units, increasing direct ownership by 36% to 32,155 units (SEC Form 4)
- Senior Vice President Ranalli Tamara A. was granted 25,751 shares (SEC Form 4)
- Chief Legal Officer Stacey Jennifer Evans was granted 38,627 shares (SEC Form 4)
- CFO Riggsbee Richard Bryan was granted 51,502 shares (SEC Form 4)
- CEO Nassif Mikheal was granted 141,631 shares (SEC Form 4)
- Neogen Corporation filed SEC Form 8-K: Leadership Update